Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
Status:
Completed
Trial end date:
2021-03-23
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the hematological safety of palbociclib with letrozole and
fulvestrant in African American women with hormone receptor positive HER2 negative advanced
breast cancer. Hematological safety is a composite endpoint of episodes of febrile
neutropenia and treatment discontinuation due to neutropenia according to current
recommendations for management of neutropenia
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Georgetown University
Collaborators:
Hackensack University Medical Center Thomas Jefferson University University of Alabama at Birmingham University of Chicago